DOCSLIB.ORG

ISMP Quarterlyactionagenda

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ISMP Quarterlyactionagenda April - June 2017 ISMP Quarterly Action Agenda One of the most important ways to prevent medication errors is to learn about problems that have occurred in other organizations and to use that information to prevent similar problems at your practice site. To promote such a process, the following selected items from the April–June 2017 issues of the ISMP Medication Safety Alert! have been prepared for leadership to use with an interdisciplinary committee or with frontline staff to stimulate discussion and action to reduce the risk of medication errors. Each item includes a brief description of the medication safety problem, a few recommendations to reduce the risk of errors, and the issue number to locate additional information. Look for our high-alert medication icon under the issue number if the agenda item involves one or more medications on the ISMP List of High-Alert Medications (www.ismp.org/sc?id=479 ). The Action Agenda is also available for download in a Microsoft Word format ( www.ismp.org/sc?id=2965 ) that allows expansion of the columns in the table designated for organizational documentation of an assessment, actions required, and assignments for each agenda item. Continuing education credit is available for nurses at: www.ismp.org/sc?id=480 . Key: — ISMP high-alert medication Issue Date Problem Recommendation Organization Assessment Action Required/Assignment No. Completed Wholesaler totes may be a source of fungal contamination (8, 9) Two hospitals reported aerosolized Regularly inspect arriving totes and fungal contamination in cleanrooms other packaging, and take immediate believed to be caused by contaminated action if needed, including follow-up wholesaler totes. In one hospital, with the wholesaler or supplier to Penicillium was discovered in both the resolve the issue. Follow best anteroom and a laminar flow hood. practices developed by CriticalPoint Soon after, practitioners noticed the (www.ismp.org/sc?id=2903 ) that call © 2 0 tote covers from the drug wholesaler for the use of a sporicidal agent when 1 7 I S had visible mold growing on them. unpacking supplies from corrugated M P Cladosporium , Aspergillus , and Penicil- cardboard boxes before bringing lium species were cultured from the them into a cleanroom. (Sterile totes. Bringing grossly contaminated isopropyl alcohol is ineffective in totes into a pharmacy increases the risk eradicating these types of micro- of contamination in the cleanroom. organisms.) Missed heparin-induced thrombocytopenia (HIT) diagnosis from heparin-coated device (9) During a procedure, a wire and catheter Compile a list of drug-eluting stents had been dipped several times in a and commercially available and/or solution containing heparin before user-applied medication-coated cath- insertion to prevent clotting. The patient eters/devices used in the facility. developed thrombocytopenia 6 days Establish a system to document in the later. A lab test for HIT was positive but patient’s record any exposure to ignored because the primary care medication-containing devices. Look physician did not know about the for hidden sources of medications if undocumented source of heparin. Once symptoms arise in patients suggesting home, the patient suffered a thrombosis possible HIT, an allergic reaction, or in his arm, requiring amputation. Hidden other drug reaction. Discontinue all and undocumented sources of heparin sources of heparin (including heparin- exposure make a diagnosis of HIT diffi - coated catheters and heparin cult. flushes), and initiate treatment if HIT is suspected or diagnosed. July 13, 2017 ISMP MedicationSafetyAlert! Ò QAA 1 April - June 2017 ISMP Quarterly Action Agenda Issue Date Problem Recommendation Organization Assessment Action Required/Assignment No. Completed Unsafe practice: Reuse of a saline flush syringes (7) A nurse was reusing prefilled saline Educate nurses about injection and flush syringes for multiple patients for 6 infusion safety, including recognition months before the unsafe practice that any form of syringe and/or needle was discovered. She believed it was reuse is dangerous. Review related cost-effective and safe if no fluids policies and procedures to ensure that were withdrawn into the syringe. the ISMP Safe Practice Guidelines for Follow-up with the 392 affected Adult IV Push Medications have been patients identified one documented incorporated ( www.ismp.org/sc?id= case of hepatitis C transmission 563 ). Monitor adherence with proper caused by reusing the flush syringes. injection and infusion techniques. Unsafe practice: Administration of a product with a precipitate (7) Six cases have been reported involving Educate nurses, physicians, pharma - dispensing and IV administration of cists, and pharmacy technicians to products despite a visible precipitate. In always observe medications and one case, a nurse administered a solutions for precipitates, and to avoid © 2 0 1 cloudy calcium gluconate and potas - dispensing or administering the 7 I S M sium phosphate infusion, which led to product if precipitates are visible or a P fatal pulmonary emboli. In another solution that should be clear is cloudy. case, a baby received 10-fold over- The use of an in-line filter for solutions doses of etoposide infusions with that are prone to precipitation can help visible precipitates for 5 days. In a third prevent particulates from entering the case, a compounding error with PRO- body; however, precipitates can still VAYBLUE (methylene blue) led to pre- form in the tubing below the filter, and cipitation of the drug, which was admin - filters may become blocked, signaling istered despite visible particulates. a need to investigate. VinCRIStine extravasation unlikely with minibags (10) Accidental mix-ups between intra- Twelve months of data collected at The thecal medications and IV vin CRIStine Johns Hopkins Hospital found zero have been uniformly fatal. One barrier cases of extravasation among 1,300 to standardizing vin CRIStine adminis - minibag administrations of IV vin- tration in minibags to prevent this error CRIStine after changing from adminis - is that some nurses believe the risk of tration via syringe ( www.ismp.org/sc? extravasation is higher than when id=2921 ). ISMP Targeted Medication administering the drug manually via IV Safety Best Practice #1 calls for dilution push. of IV vin CRIStine in a minibag to reduce the risk of mix-ups with intrathecal drugs (www.ismp.org/sc?id=417 ). July 13, 2017 ISMP MedicationSafetyAlert! Ò QAA 2 April - June 2017 ISMP Quarterly Action Agenda Issue Date Problem Recommendation Organization Assessment Action Required/Assignment No. Completed Problems associated with the use of new BD U-500 insulin syringes (9) Prescriber confusion led to the Move the “U-500” designation to the inappropriate prescribing of U-500 left of the insulin syringe entry in insulin syringes for outpatients taking prescribing systems. If U-500 syringes U-100 insulin. In another organization, are not stocked, consider using the U- U-500 syringes were repeatedly 500 insulin pen to prevent dosing errors prescribed in error via electronic rather than using a tuberculin or U-100 systems because the “U-500” desig - syringe for U-500 insulin. During med- nation was to the far right of the entry ication reconciliation, confirm the type and overlooked. Other issues include of insulin syringe or pen patients are its lack of a needle guard to protect using to administer U-500 insulin. Refer against needlesticks, and a capacity to to ISMP’s Guidelines for Optimizing measure only up to 250 units when Safe Subcutaneous Insulin Use in patients may require higher doses. Adults (www.ismp.org/sc?id=2966 ). Don’t leave “Meds to Beds” prescription bags at bedside (8) “Meds to Beds” programs bring Affix an auxiliary label to the bag of © 2 0 prescription drugs to the patient’s bed- discharge prescriptions to remind 1 7 I S M side prior to discharge and provide patients that the medications are not P pharmacists with an opportunity to for use while in the hospital. Do not educate patients about their medica - leave the medications unsecured at tions. We recently learned of an event in the bedside. A plan should be estab - which a nurse gave a patient his lis hed regarding where to secure these medications, and then the patient medications until discharge, after a opened the bag of discharge medica - pharmacist has reviewed the m with tions left at the bedside and nearly took the patient, and what to do if the patient the same medications. is not in the room at the time of delivery. Safeguard oral chloral hydrate liquid if used for pediatric procedural sedation (10) An ISMP survey indicates that oral If the drug is used in your facility, it chloral hydrate liquid is being should be prescribed in mg, not compounded in some pharmacies for volumetric doses alone. Compound the pediatric procedural sedation. About 1 drug using barcode technology (or an in 5 reported patients spitting out the independent check), and dispense it in dose or vomiting, sedation failures, and the exact prescribed amount. Only prolonged sedation. Although most do trained healthcare workers should not believe chloral hydrate has a role in administer the drug in a facility with pediatric sedation, 18% recommend its immediate access to emergency use in certain settings (e.g., radiology, equipment/medication, and the child neuroimaging, emergency department, should be monitored by a practitioner dental procedures in a hospital). once the drug has been administered. July 13, 2017 ISMP MedicationSafetyAlert! Ò QAA 3 April - June 2017 ISMP Quarterly Action Agenda Issue Date Problem Recommendation Organization Assessment Action Required/Assignment No. Completed Death due to a pharmacy compounding error (12) A lethal dose of baclofen suspension Use ready-made products whenever was administered to a child instead of possible. If compounding is necessary, tryptophan suspension due to a selec - ensure compliance with accepted tion error during the compounding standards (USP <795>) and conduct an process. The ingredients were not independent double check of all ingre - independently verified prior to com- dients prior to mixing, using barcode pounding the oral solution.
Load more

Recommended publications
  • Toxicological Review of Chloral Hydrate (CAS No. 302-17-0) (PDF)
    EPA/635/R-00/006 TOXICOLOGICAL REVIEW OF CHLORAL HYDRATE (CAS No. 302-17-0) In Support of Summary Information on the Integrated Risk Information System (IRIS) August 2000 U.S. Environmental Protection Agency Washington, DC DISCLAIMER This document has been reviewed in accordance with U.S. Environmental Protection Agency policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. Note: This document may undergo revisions in the future. The most up-to-date version will be made available electronically via the IRIS Home Page at http://www.epa.gov/iris. ii CONTENTS—TOXICOLOGICAL REVIEW for CHLORAL HYDRATE (CAS No. 302-17-0) FOREWORD .................................................................v AUTHORS, CONTRIBUTORS, AND REVIEWERS ................................ vi 1. INTRODUCTION ..........................................................1 2. CHEMICAL AND PHYSICAL INFORMATION RELEVANT TO ASSESSMENTS ..... 2 3. TOXICOKINETICS RELEVANT TO ASSESSMENTS ............................3 4. HAZARD IDENTIFICATION ................................................6 4.1. STUDIES IN HUMANS - EPIDEMIOLOGY AND CASE REPORTS .................................................6 4.2. PRECHRONIC AND CHRONIC STUDIES AND CANCER BIOASSAYS IN ANIMALS ................................8 4.2.1. Oral ..........................................................8 4.2.2. Inhalation .....................................................12 4.3. REPRODUCTIVE/DEVELOPMENTAL STUDIES ..........................13
    [Show full text]
  • Chloral Hydrate and Paraldehyde As Drugs of Addiction
    Sept., 1932J CHLORAL HYDRATE DRUG HABIT : CHOPRA & SINGH CHOPRA 481 certain parts of the Punjab. This is not the outcome of the use of the drug in the treatment Original Articles of insomnia, but is due to entirely different causes. Until a few years ago in that province potable country-made spirits were allowed to CHLORAL HYDRATE AND PARALDE' be sold to retail dealers in bulk and the vendors HYDE AS DRUGS OF ADDICTION bottled the liquor themselves. Some of these ingenious people conceived the idea of diluting R. N. m.d. By CHOPRA, m.a., (Cantab.) the spirit and adding small quantities of chloral I.M.S. LIEUTENANT-COLONEL, hydrate to make up for the loss in its potency and which would result from dilution. The know- GURBAKHSH SINGH CHOPRA, m.b., b.s. ledge that the drug had hypnotic and narcotic was obtained from the (Drug Addiction Inquiry, Indian Research Fund effects undoubtedly Association) medical profession and compounders work- in It was further learnt that Series No. 15 ing dispensaries. the effects chloral hydrate in many Chloral produced by hydrate and paraldehyde belong to resemble those by alcohol, the of ways produced group drugs known as soporifics or especially when the latter is taken in large The chief use of hypnotics. this class of drugs quantities. When the two articles are taken is in the treatment of one insomnia, of the together they act in a manner synergistic to worst evils of modern times from which man- each other and in this way the effect of either kind can suffer.
    [Show full text]
  • Chloral Hydrate Safety Issues
    December 2016 www.nursingcenter.com Chloral Hydrate Safety Issues Chloral hydrate is a sedative-hypnotic that has been associated with serious adverse events in the pediatric population including dosing errors, over-sedation, and administration of the oral liquid by the intravenous (IV) route. In 2012, commercially available chloral hydrate products were discontinued and taken off the market. However, some ambulatory and hospital pharmacies are compounding an oral suspension of chloral hydrate for pediatric sedation in both inpatient and outpatient settings. Section 503A of the Federal Food, Drug and Cosmetic Act permits pharmacists to compound chloral hydrate to provide patient specific prescriptions in limited quantities. Compounded drugs are not approved by the US Food and Drug Administration (FDA), which means the FDA does not verify the safety or effectiveness of compounded drugs. One study found that compared to the commercial formulation, the compounded drug provided a shorter duration of sedation, more frequent need for an additional sedation agent, and frequent sedation failure. Over the last two years, there have been three reported cases of pediatric chloral hydrate overdoses and one death that occurred in the outpatient setting. Respiratory depression and arrest are two serious adverse events that can occur following chloral hydrate administration. Other risks associated with chloral hydrate use include: Resedation after discharge. Chloral hydrate can result in prolonged sedation or resedation with effects lasting longer than 24 hours in children of all ages, even if they appear to have cleared the sedation prior to discharge. Chloral hydrate is converted to trichloroethanol, which has a half-life of up to 66 hours in neonates, 28-40 hours in infants, 8-12 hours in children, and longer following an overdose.
    [Show full text]
  • Chloral Hydrate
    NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDY OF CHLORAL HYDRATE (AD LIBITUM AND DIETARY CONTROLLED) (CAS NO. 302-17-0) IN MALE B6C3F1 MICE (GAVAGE STUDY) NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709 December 2002 NTP TR 503 NIH Publication No. 03-4437 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health FOREWORD The National Toxicology Program (NTP) is made up of four charter agencies of the U.S. Department of Health and Human Services (DHHS): the National Cancer Institute (NCI), National Institutes of Health; the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health; the National Center for Toxicological Research (NCTR), Food and Drug Administration; and the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention. In July 1981, the Carcinogenesis Bioassay Testing Program, NCI, was transferred to the NIEHS. The NTP coordinates the relevant programs, staff, and resources from these Public Health Service agencies relating to basic and applied research and to biological assay development and validation. The NTP develops, evaluates, and disseminates scientific information about potentially toxic and hazardous chemicals. This knowledge is used for protecting the health of the American people and for the primary prevention of disease. The studies described in this Technical Report were performed under the direction of the NCTR and were conducted in compliance with NTP laboratory health and safety requirements and must meet or exceed all applicable federal, state, and local health and safety regulations. Animal care and use were in accordance with the Public Health Service Policy on Humane Care and Use of Animals.
    [Show full text]
  • Chloral and Chloral Hydrate 247
    eHLORAL AND CHLORAL HYDRATE 1. Exposure Data 1.1 Chernical and physical data 1.1.1 Nomenclature Chloral Chem. Abstr. Serv. Reg. No.: 75-87-6 Chem. Abstr. Name: Trichloroacetaldehyde IUPAC Systematic Name: Chloral Synonyms: Anhydrous chloral; 2,2,2-trichloroacetaldehyde; trichloroethanal; 2,2,2 trichlo- roethanal Chio rai hydrate Chem. Abstr. Serv. Reg. No.: 302-17-0 Chem. Abstr. Name: 2,2,2- Trichloro-l, l-ethanediol IUPAC Systematic Name: Chloral hydrate Synonyms: Chloral monohydrate; trichloroacetaldehyde hydrate; trichloroacetaldehyde monohydrate; l,l, I-trichloro-2,2-dihydroxyethane 1.1.2 Structural and molecular formulae and relative molecular mass Ci 0 1 ~ CI-C-C L "H CI CiHCl30 Chloral Relative molecular mass: 147.39 Ci OH CI-C-C-H1 1 1 1 Ci OH CiH3Cl30i Chloral hydrate Relative molecular mass: 165.42 -245- 246 IARC MONOGRAPHS VOLUME 63 J.I.3 Chemical and physical properties of the pure substance Chloral (a) Description: Colourless, oily hygroscopic liquid with pungent, irritating odour (Budavari, 1989; EniChem America Inc., 1994) (b) Boilng-point: 97.8 °C (Lide, 1993) (c) Melting-point: -57.5 °C (Lide, 1993) (d) Density: 1.51214 at 20 °C/4 °C (Lide, 1993) (e) Spectroscopy data: Infrared (prism (4626), grating (36780)), ultraviolet (5-3), nuclear magnetic resonance (8241) and mass (814) spectral data have been reported (Sadtler Research Laboratories, 1980; Weast & Astle, 1985). (j Solubility: Soluble in water, carbon tetrachloride, chloroform, diethyl ether and ethanol (Li de, 1993; EniChem America, Inc., 1994) (g) Volatilty: Vapour
    [Show full text]
  • Chloral Hydrate and Its Effects on Multiple Physiological Parameters in Young Children: a Dose-Response Study Stephen Wilson, DMD, MA, Phd
    Chloral hydrate and its effects on multiple physiological parameters in young children: a dose-response study Stephen Wilson, DMD, MA, PhD Abstract This study evaluated the dose-responseeffect of chloral hydrate (CH)used alone on several physiological parametersin 26 healthy children 21 to 42 monthsold. Selection criteria for the children in this institutionally approvedstudy included: a) uncooperative behavior during an initial examination; b) a minimumof four sextants with caries involvement; c) healthy, ASAI; d) parental informed consent; e) a noncompromised airway (e.g., minimaltonsillar enlargement)and f) no knownallergies. A repeated measures, Latin-square design was used in evaluatingeither a placeboand three dosagesof CH(25, 50, 70 mg/kg)over four visits for each of eight patients or the samethree dosagesover three visits for each of the remainingpatients. The physiologicalparameters included: heart and respiratory rate, systolic and diastolic blood pressure, peripheral oxygen saturation, and expired carbon dioxide. For statistical purposes, physiological parameters were analyzed during specific phases which included: baseline, topical and local anesthesia administration, at initiation of cavity preparation; and at the end of the appointment. A repeated measures ANOVAand descriptive statistics wereused to analyzethe data.Theresults indicated that the diastolic blood pressureand expired carbon dioxide were affected significantly by CHdosage (P < 0.02 and 0.005, respectively). The findings should be temperedin light of patient behavior during the visits. Dental proceduresalso had an influence on cardiovascular parameters. The significance of these findings related to patient safety and behavior in these very youngchildren is discussed. (Pediatr Dent 14:171-77, 1992) Introduction Since the 1950s, most articles on sedation of children overly sensitive to mild behavioral (e.g., low-intensity for dental treatment have focused on the behavioral crying) or pharmacologic influence at moderate doses.
    [Show full text]
  • INTHE Nineteenth Century Paraldehyde and Chloral Hydrate Continued, Notwithstanding Fashions in Prescribing. As Early As Great B
    INDIVIDUAL STUDIES PATIENTS RECEIVING BARBITURATES IN AN URBAN GENERAL PRACTICE B. G. Adams, m.sc., m.r.c.p., d.p.m. Senior registrar in psychological medicine, Hammersmith Hospital and Postgraduate Medical School* and E. J. Horder, b.m., B.ch., J. P. Horder, m.r.c.p., M. MODELL, M.B., D.R.C.O.G., D.C.H., C. A. STEEN, M.B., B.S., J. W. WlGG, M.B., D.P.M. General practitioners, London, N.W.l THE nineteenth century paraldehyde and chloral hydrate INwere widely used for their hypnotic and sedative effects. The observation that urea derivatives were useful in this respect led to the synthesis of barbituric acid and the eventual clinical use of barbitone in 1903. Since then the popularity of barbiturates has continued, notwithstanding fashions in prescribing. As early as one year after their introduction into clinical practice, an account of chronic barbiturate abuse was recorded (Laudenheimer 1904). In 1946, a rough estimate of the consumption of barbiturates in Great Britain suggested that enough was produced for " one sleeping tablet per head per day for a million of the population " (Locket 1952). This calculation was based on the estimate of 71,500 lb. of barbituric acid and salts produced. Since then, the interdepartmental committee on drug addiction (1961) indicated that the estimated total quantity of barbiturate prescribed by general practitioners had increased from 90,000 to 162,000 lb. between 1951 and 1959. This occurred in spite of the introduction of other sedatives and * tran- quillizers' during this period. In 1962 the number of prescriptions for barbiturates in England and Wales totalled 15,760,000.
    [Show full text]
  • Final Report of the Addendum to The
    International Journal of Toxicology, 27(Suppl. 2f53—69, 2008 Copyright © American College of Toxicology ISSN: 1091-5818 print! 1092-874X online 001: 10.1080/10915810802244504 Final Report of the Addendum to the Safety Assessment of n-Butyl Alcohol as Used in Cosmetics’ n-Butyl Alcohol is a primary aliphatic alcohol historically used in care cosmetic products, but new concentration as a solvent nail INTRODUCTION of use data indicate that it also is being used at low concentrations in eye makeup, personal hygiene, and shaving cosmetic products. The Cosmetic Ingredient Review (CIR) evaluated the safety it-Butyl Alcohol has been generally recognized as safe for use as a of n-Butyl Alcohol (n-BuOH) in 1987, finding it safe in the flavoring substance in food and appears on the 1982 Food and Drug practices of use and concentration in nail products (Elder 1987). list of inactive ingredients for approved pre Administration (FDA) This original safety assessment was specific in that the conclu scription drug products. n-Butyl Alcohol can be absorbed through regards the use of n-Butyl Alcohol in the skin, tangs, and gastrointestinal tract. n-Butyl Alcohol may be sion was issued only as formed by hydrolysis of butyl acetate in the blood, but is rapidly nail products. oxidized. The single oral dose ED50 of n-Butyl Alcohol for rats was Recently, CIR undertook a re-review of this ingredient to de 0.79 to 4.36 g/kg. The dermal ED50 for rabbits was 4.2 g/kg. Inhala termine what additional data relevant to the safety of n-Butyl Al humans demonstrate sensory irritation of tion toxicity studies in 3.
    [Show full text]
  • TR-502: Chloral Hydrate (CASRN 302-17-0)
    NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF CHLORAL HYDRATE (CAS NO. 302-17-0) IN B6C3F1 MICE (GAVAGE STUDIES) NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709 February 2002 NTP TR 502 NIH Publication No. 02-4436 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health FOREWORD The National Toxicology Program (NTP) is made up of four charter agencies of the U.S. Department of Health and Human Services (DHHS): the National Cancer Institute (NCI), National Institutes of Health; the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health; the National Center for Toxicological Research (NCTR), Food and Drug Administration; and the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention. In July 1981, the Carcinogenesis Bioassay Testing Program, NCI, was transferred to the NIEHS. The NTP coordinates the relevant programs, staff, and resources from these Public Health Service agencies relating to basic and applied research and to biological assay development and validation. The NTP develops, evaluates, and disseminates scientific information about potentially toxic and hazardous chemicals. This knowledge is used for protecting the health of the American people and for the primary prevention of disease. The studies described in this Technical Report were performed under the direction of the NIEHS and were conducted in compliance with NTP laboratory health and safety requirements and must meet or exceed all applicable federal, state, and local health and safety regulations. Animal care and use were in accordance with the Public Health Service Policy on Humane Care and Use of Animals.
    [Show full text]
  • Mar. Biol. Ass. India, 1965, 8 (1): 28-56 EFFECTS OF
    /. Mar. biol. Ass. India, 1965, 8 (1): 28-56 EFFECTS OF ANAESTHETICS ON THE BEHAVIOUR OF MULLET FINGERLINGS AND THE SCOPE OF USING THESE IN DIFFERENT FISHERY PROCEDURES-!* By V. S. DURVE** AND S. K. DHARMA RAJA Central Marine Fisheries Research Institute, Mandapam Camp INTRODUCTION THE use of anaesthetics in fishery work, mainly in the transport of live-fish and also in handling fish for tagging, fin-clipping, weighing and stripping has been recognised by fishery workers everywhere. In live-fish transport, anaesthetics are useful in lowering the metabolic activity of fish, which facilitates the transport of more fish in a given quantity of water for a longer time. It has also been proved that anaes­ thetics make the otherwise time consuming work of tagging and fin-clipping much easier and also lower the mortality of the fish due to handling. Considerable effort has gone into a search for a proper anaesthetic and its different concentrations to give varying degrees of anaesthesia useful for works from tagging to transport of live-fish. Several methods have been used to produce anaesthesia. Abramowitz (1937), Parker (1937, 1939), Abramowitz et al. (1940) Osborn (1938, 1941) immersed fishes in crushed ice or ice water. Haskell (1940) employed electric shock to produce a paralysis lasting about two minutes. It is doubtful whether the anaesthesia induced by these methods is similar to that induced by chemicals. The disadvantages of such methods have been discussed by Pickford and Atz (1957). Chemicals used to anaesthetize fishes include Ether, Urethane, Chlorobutanol, MS-222 SANDOZ, Sodium Amytal and Chloral Hydrate, besides 8 to 9 others.
    [Show full text]
  • EPA Method 551.1: Determination of Chlorination Disinfection
    METHOD 551.1 DETERMINATION OF CHLORINATION DISINFECTION BYPRODUCTS, CHLORINATED SOLVENTS, AND HALOGENATED PESTICIDES/HERBICIDES IN DRINKING WATER BY LIQUID-LIQUID EXTRACTION AND GAS CHROMATOGRAPHY WITH ELECTRON-CAPTURE DETECTION Revision 1.0 J.W. Hodgeson, A.L. Cohen - Method 551, (1990) D.J. Munch (USEPA, Office of Water) and D.P. Hautman (International Consultants, Inc.) - Method 551.1, (1995) NATIONAL EXPOSURE RESEARCH LABORATORY OFFICE OF RESEARCH AND DEVELOPMENT U.S. ENVIRONMENTAL PROTECTION AGENCY CINCINNATI, OHIO 45268 551.1-1 METHOD 551.1 DETERMINATION OF CHLORINATION DISINFECTION BYPRODUCTS, CHLORINATED SOLVENTS, AND HALOGENATED PESTICIDES/HERBICIDES IN DRINKING WATER BY LIQUID-LIQUID EXTRACTION AND GAS CHROMATOGRAPHY WITH ELECTRON-CAPTURE DETECTION 1.0 SCOPE AND APPLICATION 1.1 This method1-9 is applicable to the determination of the following analytes in finished drinking water, drinking water during intermediate stages of treatment, and raw source water. The particular choice of analytes from this list should be a function of the specific project requirements. Analyte CAS No. Disinfection Byproducts (DBPs): Trihalomethanes Chloroform 67-66-3 Bromodichloromethane 75-27-4 Bromoform 75-25-2 Dibromochloromethane 124-48-1 Haloacetonitriles Bromochloroacetonitrile 83463-62-1 Dibromoacetonitrile 3252-43-5 Dichloroacetonitrile 3018-12-0 Trichloroacetonitrile 545-06-2 Other DBPs Chloral Hydrate 75-87-6 Chloropicrin 76-06-2 1,1-Dichloro-2-propanone 513-88-2 1,1,1-Trichloro-2-propanone 918-00-3 Chlorinated Solvents: Carbon Tetrachloride 56-23-5 1,2-Dibromo-3-chloropropane [DBCP] 96-12-8 1,2-Dibromoethane [EDB] 106-93-4 Tetrachloroethylene 127-18-4 1,1,1-Trichloroethane 71-55-6 1,1,2-Trichloroethane 79-00-5 Trichloroethylene 79-01-6 1,2,3-Trichloropropane 96-18-4 Pesticides/Herbicides: Alachlor 15972-60-8 Atrazine 1912-24-9 Bromacil 314-40-9 Cyanazine 21725-46-2 Endrin 72-20-8 551.1-2 Analyte CAS No.
    [Show full text]
  • Trichloromethyl-Heptyl Carbinol
    University of Montana ScholarWorks at University of Montana Graduate Student Theses, Dissertations, & Professional Papers Graduate School 1934 Trichloromethyl-heptyl carbinol Frank Borg The University of Montana Follow this and additional works at: https://scholarworks.umt.edu/etd Let us know how access to this document benefits ou.y Recommended Citation Borg, Frank, "Trichloromethyl-heptyl carbinol" (1934). Graduate Student Theses, Dissertations, & Professional Papers. 6667. https://scholarworks.umt.edu/etd/6667 This Thesis is brought to you for free and open access by the Graduate School at ScholarWorks at University of Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact [email protected]. TricJnlorornethyl-heptyl Carbxnol b y Pretifcnted in partial fulfillment of the requirement for the degree of Ilaa ter of te. State Unive rai ty of Sion tana 1934 Approved; r H ~ m A TTi-fvÆ ■ ______ I \Chairman of Axaminin^ Ccmmittee Chairman of Graduate Committee Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. UMI Number: EP37468 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. UMT Oissartation Publiatwtg UMI EP37468 Published by ProQuest LLC (2013). Copyright in the Dissertation held by the Author. Microform Edition © ProQuest LLC.
    [Show full text]